Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Prostate Cancer
95%
Pharmacodynamics
58%
Lysine
58%
Pharmacokinetics
58%
Phase II Trials
58%
Ascorbic Acid
58%
Docetaxel
58%
Placebo
58%
Malignant Neoplasm
25%
Biological Marker
23%
Preclinical Study
23%
Clinical Trial
20%
Monotherapy
11%
Antiproliferative Activity
11%
Drug Resistance
11%
Histone
11%
Therapeutic Window
11%
Overall Survival
9%
Progression Free Survival
9%
Adverse Event
9%
Cancer Model
7%
Side Effect
7%
Enzyme Kinetics
7%
Thrombocytopenia
7%
Crystallization
7%
Amine Oxidase (Flavin Containing) Isoenzyme A
7%
Androgen Receptor
7%
Flavine Adenine Nucleotide
7%
Tumor Growth
7%
Western Blot
7%
Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
64%
Bomedemstat
58%
Bromodomain
58%
Prostate Cancer
58%
Intravenous Vitamin C
58%
Docetaxel
58%
Phase II Trial
58%
Randomized Placebo-controlled Trial
58%
High Dose
58%
Clinical Trials
14%
Placebo Groups
13%
Confidence Interval
9%
PSA Response
9%
Prostate
9%
Prostate Radiotherapy
9%
Adverse Event Rates
9%
Clinical Outcomes
9%
Functional Assessment of Cancer Therapy
9%
Radiographic Progression-free Survival
9%
Acquired Drug Resistance
5%
Primary Drug Resistance
5%
Attractive Area
5%
Therapeutic Potential
5%
Therapeutic Targeting
5%
Predictive Biomarker
5%
Acetylated Histone
5%
Therapeutic Index
5%
Inhibitor Design
5%
Monotherapy
5%
Clinical Potential
5%
Area Cover
5%
Clinical Development
5%
Reduced Toxicity
5%
Clinical Efficacy
5%
Selective Inhibitor
5%
Expert Opinion
5%
Epigenetic Reader
5%
Preclinical Research
5%
Highly Selective
5%
Antiproliferative Activity
5%
Combination Regimen
5%